Background: Malignant phyllodes tumor (PT) is a rare fibro epithelial neoplasm of the breast, which is poor prognosis due to high risk of recurrence and distant metastasis.
Introduction
Phyllodes tumors (PTs) are unique neoplastic lesions that are comprised of both stromal and epithelial components, and they account for 0.3% to 1% of breast tumors in women. [1] PTs are subdivided into benign, borderline, and malignant categories according to histologic features. [1] Approximately 25% of PTs are considered malignancy, [2] and 20% to 50% of malignant PTs give rise to metastasis. [3] [4] [5] [6] Most of the cases, malignant PTs metastasize to lung, pleura, bone and soft tissue, [6] [7] [8] rare metastatic sites were reported including liver, [9, 10] brain, [11] [12] [13] heart, [10] mesentery, [14] spleen, [10, 11] kidney, adrenals, cervical, [10] pancreas, [9] uterus, thyroid, [11] skin. [14] Recurrence or metastasis of breast PTs predicts a shorter survival time, <1 year. [5] Here, we present a case of a female breast malignant PT patient with local recurrences and subsequent metastasis to the pelvic cavity and bone; in the end, the patient was expired after 72 months of follow-up.
Case report
A 30-year-old female patient was admitted to the hospital complaining of a mass in her left breast for 3 months. No significant signs were observed in her past medical and family history. Physical examination revealed a mass (5 cm Â 5 cm) with a clear border in the left breast. Then, the patient underwent partial mastectomy and histopathological examination revealed malignant PT.
The patient had 5 recurrences in situ later and detailed descriptions were shown in Table 1 . Additionally, axillary lymph node dissection was performed in the third relapse because of axillary lymph node metastasis. In the following months, the patient was chosen to a routine follow-up procedure.
Unexpectedly, 54 months after diagnosis, the patient came to our hospital complaining of abdominal distension. Computerized tomography (CT) scan of abdominal and pelvic revealed a colossal, lobulated, and well-defined mass in the pelvic, 14 Â 11 cm in size (Fig. 1A) . The pelvic mass was suspected as a metastasis of breast PT. Furthermore, 18 F-FDG positron emission tomogra-phy and computed tomography (FDG-PET/CT) were conducted and showed a tremendous mass with high metabolism in the pelvic cavity ( Fig. 2A and B) . Also, there was evidence of a thoracic vertebra and rib metastasis ( Fig. 2C-F Fig. 1C ). The patient did not receive radiotherapy. Subsequently, the patient experienced pelvic metastases twice 3 months or 7 months after the chemotherapy ( Fig. 1D and F) . All of the metastatic lesions were palliative treated by operation (Fig. 1E) .
The patient died 72 months after diagnosis of PT.
Discussion
The malignant PT which has a high tendency toward local recurrence and distant metastasis is uncommon in the breast. Distant metastasis developed at different time after the first diagnosis of breast PT. The average time to metastasis was 15 to 26 months; [15] however, the patient in our case occurred metastasis 54 months after diagnosis. Most distant metastasis of malignant PTs present in lungs, pleura, bone, and soft tissue ( Table 2) . Rare metastatic sites have also been showed in Table 3 . However, metastasis to pelvic cavity described in this case was not included based on our knowledge.
Operation is the basic treatment of breast PT regardless of the nature of the tumor. Wide local excision with negative margins of 1 to 2 cm is recommended. If negative margins cannot be obtained, then simple mastectomy is preferred. The efficacy between wide local excision and mastectomy is indistinct. [16] Although the possibility of local recurrence declined in patients who underwent mastectomy, overall survival did not improve when perform mastectomy. [17, 18] It was unnecessary to carry out axillary lymph node dissection with breast PT if no clinically evident involvement of axillary nodes. [18] Despite clean tumor resection and negative margin, local recurrence can hardly be avoided. The risk of relapse in malignant PTs was significantly greater than benign tumors. [19] In this case, the patient was performed partial mastectomy after initial diagnosis as PT. Consistent with the literatures reported, the patient relapsed after 17 months, subsequently, the patient experienced other 4 times local recurrence.
Whether chemotherapy could improve disease-free survival (DFS) or overall survival (OS) for PT of the breast is controversial. [20, 21] There are no randomized clinical trials proving the effectiveness of chemotherapy in malignant PT. Morales-Vazquez suggested that adjuvant chemotherapy did not improve the 5-year recurrence-free survival in patients with breast malignant PTs after surgical resection. [21] However, in the Figure 1 . CT scan showed an inhomogeneous density mass with clear border in the pelvic cavity (white arrow) (A). After pelvic tumorectomy, CT scan showed no residual tumor in the pelvic cavity (B). No recurrent lesions were detected in the CT scan after chemotherapy (C). Multiple fusion lesions were found in the pelvic cavity 3 months after chemotherapy (white arrow) (D). The recurrent lesion had shrunk to a small area with obvious enhancement after surgical treatment (E). CT scan displayed that ill-defined lesions increased (white arrow) (F). CT = computed tomography. patients with metastasis PT, chemotherapy should be considered the optimal treatment. [22] Hawkins presented a case which received combination chemotherapy as soon as metastasis appeared had 61 months disease-free survival, which was longer than other available literatures. [20] Radiotherapy plays a major role in the prevention of postoperative recurrence of several solid tumors. While currently, there is no consensus on the role of radiotherapy in malignant PT. [23] Pandey et al [24] and Belkacemi et al [25] suggested that adjuvant radiotherapy after surgery had no significant impact on disease-free survival or overall survival. In the report from the Surveillance Epidemiology and End Results (SEER) Program on 821 malignant PTs, radiotherapy plus surgery predicted for worse cancer-specific survival compared with surgery alone. [16] Local recurrence is a risk factor of tumor distant metastasis. Most distant metastasis of breast PT took place after local recurrence. [9, 26] However, other investigators did not observe the association between local recurrence and systemic spread. [24] Moreover, local recurrence can be salvaged by secondary surgery. [25] Whether the local recurrence is a predictive factor for metastasis of breast PT is still elusive. [5] A study suggested that tumor size tended to be an independently predictive factor for local recurrence. [9] Strong CEA expression in the epithelia correlated with local recurrence of PT of the breast, therefore, suitable to predict the clinical course of the disease. [27] In addition, genetic abnormalities were pointed out to be responsible for recurrences of PT, especially 1q gain mapped to 1q21-23 region and 3p loss mapped to the FHIT gene in the 3p12-14 region. [28] Tumor distant metastasis is the main cause of survival threatening. As long as the breast PT progresses to distant metastasis, its prognosis is unfavorable, and median survival ranges from 5 to 24 months. [4, 6, 15, 29] Our described patient gave rise to metastases after 54 months of first diagnosis and then died after 72 months. Microscopically, histology features of malignant PT are clear stromal cellular atypia, marked stromal overgrowth, infiltrating tumor margins, and >10/10 HPF of mitotic activity. Stromal cellularity, stromal overgrowth, tumor margin, and mitotic activity were all significantly correlated with distant metastases. [17] It has been noted that 87.5% of PTs which had a characterization of mitotic activity greater than 15/10 HPF finally metastasized. [30] MiR-21 played a crucial role in the molecular pathogenesis of PT metastasis. It induced myofibroblast www.md-journal.com differentiation, subsequently regulated migration, and promoted metastasis. [31] Autophagy-related protein LC3A expression in the stromal component of PT was significantly associated with distant metastasis. [32] Metastatic PTs had a remarkably higher stromal CD10 expression, and cases with negative CD10 expression did not metastasized. [33, 34] High expression of CD10, as a metalloprotease, might increase the potential of metastasis by providing tumors with the capacity of invading vessel walls. [33] However, these markers are still not powerful prediction in clinical practice. [27, 28, 34] It is important to identify Table 2 Reported common metastatic sites for phyllodes tumor.
Metastatic sites Percentage
Lung [6, 9, 10, 13, 35] 41.7-91.0% Pleura [6, 9, 14] 11.1-67.0% Bone [6, 9, 10, 13] 20.0-44.0% Soft tissue [9, 14] 37.5-58.3% Thoracic cavity [9] 33.3% Viscera [14] 15.0% Gastrointestinal tract [36] <1.0% Table 3 Clinical characteristics, pathological findings, and follow-up of 20 patients with phyllodes tumor metastasize to rare sites.
some reliable factors to predict recurrence of PT and manage patients in early period.
Conclusion
Current case represented a malignant breast PT with local recurrences and an extraordinary localization of metastasis (pelvic cavity), but the patient possessed of long-term survival following operation and chemotherapy. From the case report of our study, we proposed that reliable predictive factors should be explored to identify patients at high risk of local recurrence and distant metastasis. Although breast PTs have unfavorable prognosis, there is no standardized therapeutic strategy for it, so there is urgent need to perform well-designed prospective studies for investigating the roles of different strategies in treatment of breast PT.
